Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 4/20 | 1.00 |
| ▸ | TRPA1 | O75762 | 1/20 | 1.00 |
| ▸ | EPHX2 | P34913 | 1/20 | 1.00 |
| ▸ | FAAH2 | Q6GMR7 | 1/20 | 1.00 |
| ▸ | MGLL | Q99685 | 1/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Urb-597 SCHEMBL29371698 | 1.00 | FAAH (1.00) | FAAHTRPA1EPHX2FAAH2MGLL | |
| SCHEMBL14187855 | 0.99 | FAAH (0.98) | FAAHTRPA1EPHX2FAAH2MGLL | |
| SCHEMBL17175654 | 0.96 | FAAH (0.93) | FAAHTRPA1EPHX2FAAH2MGLL | |
| SCHEMBL4750537 | 0.92 | FAAH (0.86) | FAAHTRPA1EPHX2FAAH2MGLL | |
| SCHEMBL10089400 | 0.92 | FAAH (0.84) | FAAHTRPA1EPHX2FAAH2MGLL | |
| SCHEMBL14188106 | 0.90 | FAAH (0.82) | FAAHTRPA1EPHX2FAAH2MGLL | |
| SCHEMBL16118260 | 0.90 | FAAH (0.81) | FAAHTRPA1EPHX2FAAH2MGLL | |
| SCHEMBL14722820 | 0.90 | FAAH (0.81) | FAAHTRPA1EPHX2FAAH2MGLL | |
| SCHEMBL17165898 | 0.89 | FAAH (1.00) | FAAHTRPA1EPHX2FAAH2MGLL | |
| SCHEMBL18685448 | 0.89 | FAAH (0.80) | FAAHTRPA1EPHX2FAAH2MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 346 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220016046-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2022-01-20 | — | — | US | claimed |
| US-20210290561-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2021-09-23 | — | — | US | claimed |
| US-20210186906-A1 | METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-06-24 | — | — | US | claimed |
| EP-2995303-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | President and Fellows of Harvard College (US) | 2016-03-16 | — | — | EP | claimed |
| EP-2101819-B1 | METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITIS | HARVARD COLLEGE (US) | 2013-01-09 | — | — | EP | claimed |
| US-20120172429-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI- INFLAMMATORY AGENTS | THE GENERAL HOSPITAL CORPORATION | 2012-07-05 | — | — | US | claimed |
| EP-2451944-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | President and Fellows of Harvard College (US) | 2012-05-16 | — | — | EP | claimed |
| JP-2011513484-A | — | — | 2011-04-28 | — | — | JP | claimed |
| US-20110086818-A1 | METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITUS | PRESIDENTS AND FELLOWS OF HARVARD COLLEGE (US) | 2011-04-14 | — | — | US | claimed |
| WO-2011006073-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-01-13 | — | — | WO | claimed |
| EP-2271329-A2 | METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITIS | President and Fellows of Harvard College (US) | 2011-01-12 | — | — | EP | claimed |
| EP-2101819-A2 | METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-09-23 | — | — | EP | claimed |
| WO-2009114139-A2 | METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-09-17 | — | — | WO | claimed |
| WO-2008063603-A2 | METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2008-05-29 | — | — | WO | claimed |
| EP-3938345-B1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | NOCION THERAPEUTICS INC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260116859-A1 | Charged Ion Channel Blockers and Methods for Use | NOCION THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260103492-A1 | CYCLOSPORINE COMPOSITIONS AND METHODS OF USE | BACAINN BIOTHERAPEUTICS, LTD. (KY) | 2026-04-16 | — | — | US | disclosed |
| EP-1558591-A2 | MODULATION OF ANXIETY THROUGH BLOCKADE OF ANANDAMIDE HYDROLYSIS | The Regents of the University of California (US) | 2005-08-03 | — | — | EP | disclosed |
| US-20040127518-A1 | Modulation of anxiety through blockade of anandamide hydrolysis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-07-01 | — | — | US | disclosed |
| WO-2004033422-A2 | MODULATION OF ANXIETY THROUGH BLOCKADE OF ANANDAMIDE HYDROLYSIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260103492-A1 | CYCLOSPORINE COMPOSITIONS AND METHODS OF USE | ABCC1, SLC47A2, ABCB1 | FAAH 2184/4885TRPA1 958/4885EPHX2 3705/4885 |
| US-20120172429-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI- INFLAMMATORY AGENTS | TRPV1, CACNA1B, ORAI1 | FAAH 615/4885TRPA1 13/4885EPHX2 2052/4885 |
| US-20110086818-A1 | METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITUS | TRPV1, OPRL1, ITCH | FAAH 238/4885TRPA1 4/4885EPHX2 980/4885 |
| US-20260116859-A1 | Charged Ion Channel Blockers and Methods for Use | OPRL1, TRPV1, SCN2B | FAAH 913/4885TRPA1 13/4885EPHX2 870/4885 |
| US-20040127518-A1 | Modulation of anxiety through blockade of anandamide hydrolysis | FAAH, FAAH2, CNR2 | FAAH 1/4885TRPA1 847/4885EPHX2 34/4885 |
| US-20210290561-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | TRPV1, CACNA1B, ORAI1 | FAAH 615/4885TRPA1 13/4885EPHX2 2052/4885 |
| US-20220016046-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | CACNA1B, TRPV1, ORAI1 | FAAH 631/4885TRPA1 16/4885EPHX2 2135/4885 |
| US-20210186906-A1 | METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITIS | TRPV1, TRPV2, TRPV3 | FAAH 197/4885TRPA1 4/4885EPHX2 818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.